Physician profile
Stevan A Smallow
NPI 1063434520
$179.41
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.37 | 2019 | |
| Amarin Pharma, INC. | $22.41 | 2019 | |
| Orexo US, INC. | $17.33 | 2019 | |
| Alkermes, INC. | $15.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.98 | 2019 | |
| Lilly USA, LLC | $12.94 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stevan Smallow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.